Back

Comprehensive cardiovascular magnetic resonance for evaluating structural myocardial changes in patients with hypertrophic obstructive cardiomyopathy treated with the first myosin inhibitor

1 September 2025 (10:10 - 10:20)
Organised by: Logo
Congress Presentation Part of: Prognostic imaging in hypertrophic cardiomyopathy and amyloidosis Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Leni Katharina Seuthe

Cologne University Hospital - Heart Center, Cologne (Germany)

5 More presentations in this session

Presentation thumbnail
Assessment of left ventricular function measured with cardiac MRI feature tracking predicts heart failure events in childhood hypertrophic cardiomyopathy
Doctor X. Chen (Beijing, CN)
Abstract Slides
Presentation thumbnail
CMR-based assessment of left ventricular hemodynamics in obstructive hypertrophic cardiomyopathy treated with septal reduction therapy
Ms M. Yu (Sichuan, CN)
Abstract Slides
Presentation thumbnail
The PA/Ao ratio as a predictor for adverse outcomes in light-chain vs. transthyretin cardiac amyloidosis
Mr L. List (Vienna, AT)
Abstract Slides
Presentation thumbnail
Novel thresholds for all-cause mortality risk stratification in hypertrophic cardiomyopathy using cardiac magnetic resonance- late gadolinium enhancement
Miss S. Arshanapalli (London, GB)
Abstract Slides
Presentation thumbnail
Cardiovascular magnetic resonance late gadolinium enhancement risk score for mortality in hypertrophic cardiomyopathy: the HCM-LGE risk score
Doctor J. Florence (Paris, FR)
Abstract Slides

Access the full session

Session thumbnail
Prognostic imaging in hypertrophic cardiomyopathy and amyloidosis
Video

The Event

Event poster

ESC Congress 2025

1 September 2025 10:10 CET
You may be interested in
thumbnail
Congress Session
Advanced imaging in heart failure
thumbnail
Congress Session
Ventricular arrhythmias and prevention of sudden cardiac death (1)
thumbnail
Webinar
The role of cardiac magnetic resonance for patients with ventricular arrhythmias and the prevention of sudden cardiac death in light of the 2022 ESC Guidelines

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources